OneMedNet

ONMD on Nasdaq. OneMedNet sells clinical imaging data and patient records to life science partners. Market value $317m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
-25.8%low

For every $100 of what the whole company costs, it produced $-25.79 of spare cash last year. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 30 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$4.70 a share, 30% above its 1-year low

Over the past year the price has ranged from $3.61 to $23.00.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.0
-0.0
-0.0
-0.0
2022202320242025
Revenue
$1m$1m$643,000$1m
Operating margin
-669.1%-671.2%-1493.8%-711.3%
Debt to equity
n/an/an/an/a
Shares outstanding
0.03bn0.03bn0.05bn0.01bn

Health checks

  • Free cash flow positive0 of 4 years
  • Accounting checksSkipped: company is not yet profitable
  • DebtUnknown
  • Revenue growth, five yearsSlow, 5.6% a year
  • Buying back its own sharesYes, 81% fewer since 2022

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1 million last quarter, up 478% on a year ago.
  • A loss of $3 million, compared with a loss of $741,000 a year ago.
  • It loses 440 cents on each $1 of sales, compared with 1883 cents a year earlier.
  • 17% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in 3 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$26,000
March 2025$137,000
June 2025$155,000
September 2025$177,000
December 2025$891,000
March 2026$96,000
June 2026$292,000
September 2026$1m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$2m
March 2025-$2m
June 2025$3m
September 2025-$741,000
December 2025-$3m
March 2026-$2m
June 2026-$2m
September 2026-$3m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
30 March 2026
Next quarterly (estimated, 10-Q)
15 February 2027

Who owns it

None of the long-term investors we follow own it. 22 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

No one has reported a stake above 5% since December 2024.

  • TD SECURITIES (USA) LLC
    Passive investor
    Sold down below 5%
    Since 30 September 2026
  • Off the Chain LP
    Passive investor
    Sold down below 5%
    Since 30 September 2026
  • DISCOVERY CAPITAL MANAGEMENT, LLC
    Passive investor
    Sold down below 5%
    Since 30 September 2025
  • COWEN AND COMPANY, LLC
    Passive investor
    Sold down below 5%
    Since 31 December 2024

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 3 insiders bought $4m of shares on the open market. 2 sold $103,052.

  • Yu Jeffrey
    Chief Medical Officer, Director
    Bought
    Date
    9 October 2026
    Shares
    45,126
    Price
    $5.54
    Value
    $249,998
  • Kosasa Thomas
    Director
    Bought
    Date
    7 October 2026
    Shares
    129,758
    Price
    $5.78
    Value
    $750,001
  • Green Aaron
    Chief Executive Officer, Director
    Sold
    Date
    24 September 2026
    Shares
    1,667
    Price
    $6.48
    Value
    $10,802
  • Green Aaron
    Chief Executive Officer, Director
    Sold
    Date
    22 September 2026
    Shares
    5,000
    Price
    $7.39
    Value
    $36,960
  • Golden Robert Lawrence
    Chief Financial Officer, Director
    Sold
    Date
    21 September 2026
    Shares
    3,000
    Price
    $6.63
    Value
    $19,890
  • Golden Robert Lawrence
    Chief Financial Officer, Director
    Sold
    Date
    15 September 2026
    Shares
    3,000
    Price
    $6.30
    Value
    $18,900
  • Golden Robert Lawrence
    Chief Financial Officer, Director
    Sold
    Date
    14 September 2026
    Shares
    2,500
    Price
    $6.60
    Value
    $16,500
  • Yu Jeffrey
    Chief Medical Officer, Director
    Bought
    Date
    10 September 2026
    Shares
    142,857
    Price
    $0.63
    Value
    $90,000
  • Kosasa Thomas
    Director
    Bought
    Date
    30 July 2026
    Shares
    1,449,275
    Price
    $0.69
    Value
    $1,000,000
  • Green Aaron
    Chief Executive Officer, Director
    Bought
    Date
    23 June 2026
    Shares
    36,650
    Price
    $0.57
    Value
    $20,891

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

2 serious warning signs in OneMedNet’s filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 8 later 8-Ks.

  • Doubt it can keep going

    Serious

    The company or its auditor warned it may not have enough money to last the next year.

    “As a result of the Company’s recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.”
    Show the full paragraph
    Currently, management does not believe that our cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months. Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management intends to raise cash for operations through debt and equity offerings. As a result of the Company’s recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.

    From the 10-Q filed 16 November 2026, Part I, Item 2. Management's Discussion and Analysis. Read it in the filing

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to material weaknesses in our internal controls over financial reporting related to user access and segregation of duties, the lack of a formalized control environment and oversight of controls over financial reporting, and revenue recognition.”
    Show the full paragraph
    Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), as of September 30, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to material weaknesses in our internal controls over financial reporting related to user access and segregation of duties, the lack of a formalized control environment and oversight of controls over financial reporting, and revenue recognition.

    From the 10-Q filed 16 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

  • It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.